EHDN 2021 Remote Meeting
Asset 49
Cantor Virtual Global Healthcare Conference
C-Path Neuroscience annual meeting




September 10 | 2021

Prilenia to Present at Upcoming Virtual Healthcare Events 

July 12 | 2021

FDA Grants Orphan Drug Designation for pridopidine for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

July 8 | 2021

Prilenia’s Phase 3 Huntington’s Disease Clinical Trial Achieves
50% Enrollment

June 29 | 2021

​Prilenia receives positive EMA opinion on Orphan Drug Designation 
for pridopidine in ALS 

May 28 | 2021

Prilenia to Present at Jefferies Virtual Healthcare Conference

May 25 | 2021

New research supports pridopidine’s neuroprotective properties in Huntington’s Disease models

May 13 | 2021

Prilenia Achieves 25% Enrollment in its phase 3 HD trial and appoints

Dr. Goldberg as CSO 

April 1 | 2021

​​Prilenia to Present at Stifel, BMO, Needham and the European Biotech Investor Days 

March 8 | 2021

Prilenia to Present at Upcoming Virtual Healthcare Conferences 

January 28 | 2021

Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease

January 8 | 2021

Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS

December 16 | 2020

Additional analyses of Efficacy and Safety of Pridopidine for Huntington’s Disease demonstrate positive effect on functional capacity

October 27 | 2020

Prilenia Enrolls First Patients into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United State

September 17 | 2020

Huntington Study Group Announces A Partnership with Prilenia Therapeutics to Conduct A Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease

September 10 | 2021

Henk Schuring joins Prilenia as Chief Regulatory and Commercialization Officer

June 3 | 2020

Prilenia Therapeutics raises $62.5M to fund late stage trials in HD and ALS

June 3 | 2020

Presentation by Dr. Michael Hayden at the Jefferies Virtual Conference 

September 18 | 2019

Prilenia’s Pridopidine chosen to participate in the first ever ALS platform trial by the Sean M. Healey & AMG center for ALS at Mass General